KIRYAT HADASSAH, MINRAV BUILDING, JERUSALEM, L3
Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation
Second Quarter 2026 Financial Results and Business Updates
News, Material Contracts
Shareholders Approve Amendment to 2018 Equity Incentive Plan
Annual Report to Security Holders
First oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – Phase 3 protocol submitted with FDA feedback expected imminently; incremental data submitted to ENDO2026 and first oral long-acting PTH peptide replacement tablet for hypoparathyroidism – Expanded 50/50 partnership; intention to file IND in late 2026; data submitted to ENDO2026 first
First Oral Anabolic (Bone Building) Peptide Tablet for Postmenopausal Women with Osteoporosis – FDA Type A Endpoint Alignment in July 2025
Q2
Q1
FY 2025
Q3
FY 2024
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload